# Moelis & Co: financial statements, quarterly

MC · NYSE · CIK 1596967 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mc.md) · [Financials](/companies/mc/financials.md) · [Filings](/companies/mc/filings.md) · [Insiders](/companies/mc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating income | $m | [(20.0)](/filings/0000950170-24-116726.md) | [(9.3) d](/filings/0001193125-26-076747.md) | [5.8](/filings/0000950170-25-057541.md) | [20.1](/filings/0000950170-25-098436.md) | [15.6](/filings/0001193125-25-256727.md) | [132 d](/filings/0001193125-26-076747.md) | [36.9](/filings/0001193125-26-192462.md) | [60.6](/filings/0001193125-26-324296.md) | [48.3](/filings/0001193125-25-256727.md) | [128 d](/filings/0001193125-26-076747.md) | [40.5](/filings/0001193125-26-192462.md) | [72.8](/filings/0001193125-26-324296.md) |
| Income tax | $m | [1.3](/filings/0000950170-24-116726.md) | [2.3 d](/filings/0001193125-26-076747.md) | [(7.5)](/filings/0000950170-25-057541.md) | [6.9](/filings/0000950170-25-098436.md) | [7.4](/filings/0001193125-25-256727.md) | [37.7 d](/filings/0001193125-26-076747.md) | [(10.7)](/filings/0001193125-26-192462.md) | [17.4](/filings/0001193125-26-324296.md) | [22.2](/filings/0001193125-25-256727.md) | [39.0 d](/filings/0001193125-26-076747.md) | [3.9](/filings/0001193125-26-192462.md) | [20.2](/filings/0001193125-26-324296.md) |
| Net income | $m | [(11.4)](/filings/0000950170-24-116726.md) | [(6.5) d](/filings/0001193125-26-076747.md) | [17.5](/filings/0001193125-25-256727.md) | [14.9](/filings/0001193125-25-256727.md) | [19.2](/filings/0001193125-25-256727.md) | [99.8 d](/filings/0001193125-26-076747.md) | [53.8](/filings/0001193125-26-324296.md) | [46.8](/filings/0001193125-26-324296.md) | [60.1](/filings/0001193125-25-256727.md) | [99.0 d](/filings/0001193125-26-076747.md) | [42.3](/filings/0001193125-26-324296.md) | [55.1](/filings/0001193125-26-324296.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss
- Diluted EPS: not reported
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [147](/filings/0000950170-23-058409.md) | [186](/filings/0000950170-25-029070.md) | [103](/filings/0000950170-24-047744.md) | [150](/filings/0000950170-24-086165.md) | [145](/filings/0000950170-24-116726.md) | [412](/filings/0001193125-26-076747.md) | [185](/filings/0000950170-25-057541.md) | [222](/filings/0000950170-25-098436.md) | [282](/filings/0001193125-25-256727.md) | [509](/filings/0001193125-26-324296.md) | [153](/filings/0001193125-26-192462.md) | [208](/filings/0001193125-26-324296.md) |
| Total assets | $m | [1,120](/filings/0000950170-23-058409.md) | [1,180](/filings/0000950170-25-029070.md) | [1,012](/filings/0000950170-24-047744.md) | [1,051](/filings/0000950170-24-086165.md) | [1,153](/filings/0000950170-24-116726.md) | [1,379](/filings/0001193125-26-076747.md) | [1,206](/filings/0000950170-25-057541.md) | [1,343](/filings/0000950170-25-098436.md) | [1,517](/filings/0001193125-25-256727.md) | [1,741](/filings/0001193125-26-324296.md) | [1,289](/filings/0001193125-26-192462.md) | [1,408](/filings/0001193125-26-324296.md) |
| Total liabilities | $m | [740](/filings/0000950170-23-058409.md) | [817](/filings/0000950170-25-029070.md) | [620](/filings/0000950170-24-047744.md) | [666](/filings/0000950170-24-086165.md) | [758](/filings/0000950170-24-116726.md) | [900](/filings/0001193125-26-076747.md) | [640](/filings/0000950170-25-057541.md) | [747](/filings/0000950170-25-098436.md) | [899](/filings/0001193125-25-256727.md) | [1,060](/filings/0001193125-26-324296.md) | [667](/filings/0001193125-26-192462.md) | [767](/filings/0001193125-26-324296.md) |
| Shareholders' equity | $m | [367](/filings/0000950170-23-058409.md) | [352](/filings/0000950170-25-029070.md) | [364](/filings/0000950170-24-047744.md) | [358](/filings/0000950170-24-086165.md) | [368](/filings/0000950170-24-116726.md) | [442](/filings/0001193125-26-076747.md) | [485](/filings/0000950170-25-057541.md) | [516](/filings/0000950170-25-098436.md) | [535](/filings/0001193125-25-256727.md) | [568](/filings/0001193125-26-324296.md) | [487](/filings/0001193125-26-192462.md) | [506](/filings/0001193125-26-324296.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [140 d](/filings/0000950170-24-116726.md) | [99.3 d](/filings/0001193125-26-076747.md) | [(165)](/filings/0000950170-25-057541.md) | [140 d](/filings/0000950170-25-098436.md) | [137 d](/filings/0001193125-25-256727.md) | [315 d](/filings/0001193125-26-076747.md) | [(165)](/filings/0001193125-26-192462.md) | [204 d](/filings/0001193125-26-324296.md) | [199 d](/filings/0001193125-25-256727.md) | [339 d](/filings/0001193125-26-076747.md) | [(279)](/filings/0001193125-26-192462.md) | [230 d](/filings/0001193125-26-324296.md) |
| Capital expenditure | $m | [4.7 d](/filings/0000950170-24-116726.md) | [5.3 d](/filings/0001193125-26-076747.md) | [5.4](/filings/0000950170-25-057541.md) | [2.3 d](/filings/0000950170-25-098436.md) | [2.1 d](/filings/0001193125-25-256727.md) | [2.3 d](/filings/0001193125-26-076747.md) | [3.1](/filings/0001193125-26-192462.md) | [4.8 d](/filings/0001193125-26-324296.md) | [19.3 d](/filings/0001193125-25-256727.md) | [9.2 d](/filings/0001193125-26-076747.md) | [12.8](/filings/0001193125-26-192462.md) | [13.7 d](/filings/0001193125-26-324296.md) |
| Dividends paid | $m | [44.5 d](/filings/0000950170-24-116726.md) | [44.7 d](/filings/0000950170-25-029070.md) | [39.3](/filings/0000950170-25-057541.md) | [51.5 d](/filings/0000950170-25-098436.md) | [47.6 d](/filings/0000950170-24-116726.md) | [45.9 d](/filings/0000950170-25-029070.md) | [45.1](/filings/0000950170-25-057541.md) | [59.1 d](/filings/0000950170-25-098436.md) | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.